Amgen Down Nearly 7%, On Pace For Largest Percent Decrease Since March 2020 — Data Talk
Amgen Inc AMGN
News
Beneath the surface, the next stock-market leaders are getting ready to break out, says Morgan Stanley
Why the Dow is being dragged down by a Swiss company's bad news
FTC Challenges Amgen's Patent Play in Enbrel Antitrust Case
Moderna's cancer-vaccine breakthrough drives broad biopharma stock rally
Amgen Lifts Outlook on Strong 2Q Drug Sales, to End Early Development of Obesity Treatment
European Regulator Calls for Amgen's Tavneos to Have Authorization Revoked
Kissei Revises Package Insert in Japan for Amgen's Tavneos
Amgen Names Thomas Dittrich as Finance Chief
Amgen to Invest $300 Million in Expanding Puerto Rico Biologics Plant
Amgen Down Nearly 5%, on Pace for Largest Percent Decrease Since August 2025 — Data Talk
Amgen Posts Higher 1Q Profit, Revenue
Viridian Shares Fall After Competing Amgen Eye Drug Performs Well
Amgen Posts Strong Phase 3 Trial Data for Subcutaneous Tepezza
Zai Lab, Amgen Team Up for Lung Cancer Clinical Trial
FDA Says Amgen's Tavneos Linked to Liver Injuries, Deaths — Update
FDA Says Amgen's Tavneos Linked to Liver Injuries, Deaths
Amgen Logs Higher 4Q Revenue on Double-Digit Volume Boost
Amgen, Kyowa Kirin Ending Atopic Dermatitis Drug Collaboration
Amgen Buys Dark Blue Therapeutics in Deal Worth Up to $840 Million
United States